Literature DB >> 10800760

GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

A Corrias1, J Bellone, L Beccaria, L Bosio, G Trifirò, C Livieri, L Ragusa, A Salvatoni, M Andreo, P Ciampalini, G Tonini, A Crinò.   

Abstract

Basal IGF-I levels and the GH response to at least two among provocative stimuli such as clonidine (CLO, Catapresan, 150 mcg/m2 p.o.), GHRH (1 mcg/kg i.v.)+arginine (ARG, 0.5 g/kg i.v. infusion during 30 min) and GHRH+pyridostigmine (PD, Mestinon cpr 60 mg p.o.) have been evaluated in 43 children with Prader-Willi syndrome (PWS, 17 males and 26 females, age 3-22 yr, 7 normal weight and 36 obese PWS), in 25 normal short children (NC, 17 males and 8 females, 7.7-18.5 yr) and in 24 children with simple obesity (OB, 14 males, 10 females, 7.7-21.5 yr). Both normal weight and obese PWS had mean IGF-I levels lower than those recorded in NC (p<0.001) and OB (p<0.001). The GH responses to GHRH+ARG and GHRH+PD in NC were similar and higher than that to CLO (p<0.001). In PWS the GH response to GHRH+ARG was higher than that to GHRH+PD (p<0.001) which, in turn, was higher than that to CLO (p<0.001); these responses in PWS were lower than those in normal children (p<0.02) and similar to those in OB. In normal weight PWS the GH responses to GHRH+ARG and to GHRH+PD were similar and higher than to CLO (p<0.05); however, each provocative stimulus elicited a GH rise lower than that in NC (p<0.05). In obese PWS as well as in OB the GH response to GHRH+ARG was higher than that to GHRH+PD (p<0.02) which, in turn, was higher than that to CLO (p<0.001); all GH responses in obese PWS and OB were lower than those in NC (p<0.001) but similar to those in normal weight PWS. In conclusion, patients with PWS show clear reduction of IGF-I levels as well as of the somatotroph responsiveness to provocative stimuli independently of body weight excess. These results strengthen the hypothesis that PWS syndrome is frequently connotated by GH insufficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10800760     DOI: 10.1007/bf03343684

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.

Authors:  M Angulo; M Castro-Magana; B Mazur; J A Canas; P M Vitollo; M Sarrantonio
Journal:  J Pediatr Endocrinol Metab       Date:  1996 May-Jun       Impact factor: 1.634

2.  Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition.

Authors:  S Loche; M Cappa; P Borrelli; A Faedda; A Crinò; S G Cella; R Corda; E E Müller; C Pintor
Journal:  Clin Endocrinol (Oxf)       Date:  1987-08       Impact factor: 3.478

3.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

4.  Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.

Authors:  E Ghigo; E Mazza; A Corrias; E Imperiale; S Goffi; E Arvat; J Bellone; C De Sanctis; E E Müller; F Camanni
Journal:  Metabolism       Date:  1989-07       Impact factor: 8.694

5.  Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan.

Authors:  M R Valetto; J Bellone; C Baffoni; P Savio; G Aimaretti; L Gianotti; E Arvat; F Camanni; E Ghigo
Journal:  Eur J Endocrinol       Date:  1996-11       Impact factor: 6.664

6.  Inter- and intrachromosomal rearrangements are both involved in the origin of 15q11-q13 deletions in Prader-Willi syndrome.

Authors:  R Carrozzo; E Rossi; S L Christian; K Kittikamron; C Livieri; A Corrias; L Pucci; A Fois; P Simi; L Bosio; L Beccaria; O Zuffardi; D H Ledbetter
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

7.  Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.

Authors:  G Grugni; G Guzzaloni; D Moro; D Bettio; C De Medici; F Morabito
Journal:  Clin Endocrinol (Oxf)       Date:  1998-06       Impact factor: 3.478

8.  Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.

Authors:  M Cappa; A Grossi; P Borrelli; E Ghigo; J Bellone; S Benedetti; D Carta; S Loche
Journal:  Horm Res       Date:  1993

9.  Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.

Authors:  M Maccario; M Procopio; S Grottoli; S E Oleandri; G M Boffano; M Taliano; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1996-03       Impact factor: 8.694

10.  Prader-Willi syndrome: consensus diagnostic criteria.

Authors:  V A Holm; S B Cassidy; M G Butler; J M Hanchett; L R Greenswag; B Y Whitman; F Greenberg
Journal:  Pediatrics       Date:  1993-02       Impact factor: 7.124

View more
  16 in total

Review 1.  Growth hormone therapy in the Prader-Willi syndrome.

Authors:  W F Paterson; M D C Donaldson
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

Review 2.  Growth hormone treatment in non-growth hormone-deficient children.

Authors:  Sandro Loche; Luisanna Carta; Anastasia Ibba; Chiara Guzzetti
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-03-31

3.  Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Authors:  G Grugni; G Guzzaloni; F Morabito
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

4.  Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.

Authors:  Roja Motaghedi; Elizabeth G Lipman; Jeannette E Hogg; Paul J Christos; Maria G Vogiatzi; Moris A Angulo
Journal:  Eur J Med Genet       Date:  2010-10-20       Impact factor: 2.708

5.  Growth hormone treatment in a girl with Prader Willi syndrome.

Authors:  S N Pandey; R A Vaidya; A Irani
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

6.  Short-term effects of growth hormone treatment on the upper airways of non severely obese children with Prader-Willi syndrome.

Authors:  A Salvatoni; E Veronelli; L Nosetti; J Berini; S de Simone; L Iughetti; L Bosio; G Chiumello; G Grugni; G Delù; P Castelnuovo; G Trifirò; L Nespoli
Journal:  J Endocrinol Invest       Date:  2009-05-15       Impact factor: 4.256

7.  Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome.

Authors:  Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

Review 8.  Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy.

Authors:  Krystal A Irizarry; Mark Miller; Michael Freemark; Andrea M Haqq
Journal:  Adv Pediatr       Date:  2016-08

9.  Central precocious puberty and growth hormone deficiency in a boy with Prader-Willi syndrome.

Authors:  Antonino Crinò; Girolamo Di Giorgio; Riccardo Schiaffini; Alessandra Fierabracci; Sabrina Spera; Andrea Maggioni; Guido Castelli Gattinara
Journal:  Eur J Pediatr       Date:  2008-02-27       Impact factor: 3.183

Review 10.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.